PATENT 0020-5314PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

Hitoshi BAN et/al.

Conf.:

Unassigned

Appl. No.:

10/511,319

Group:

Unassigned

Filed:

October 15, 2004

Examiner: UNASSIGNED

For:

NOVEL PIPERIDINE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION AFTER FILING OF AN APPLICATION
BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE
OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 December 6, 2004

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

II. COPIES (check at least one box)

- a. Copies of cited U.S. patents and patent application publications are not included. Copies of foreign patent documents and non-patent literature are included.
- b. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ENGLISH LANGUAGE SEARCH REPORT


An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. 🛛 OTHER

The following additional information is provided for the Examiner's consideration.

- Masuda et al., Arteriosclerosis, Vol. 10, Pages 164-177, (1990) is referenced on page 1 of the specification.
- Brecher et al., Biochimica et Biophysica, Vol. 617, Pages 458-471 is referenced on page 2 of the specification.
- Krause et al., Journal of Lipid Research, Vol. 34, Pages 279-294, (1993) is referenced on page 2 of the specification.
- EP 0 344 425 A2 is the counterpart of JP-A-6456 and is referenced on page 2 of the specification.
- EP 0 335 375 A2 is the counterpart of JP-A-6457 and is referenced on page 2 of the specification.
- EP 0 293 880 Al is referenced on page 2 of the specification.

FEES



VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box) The undersigned hereby states that a. each item of information contained in the IDS was first cited in any communication from a foreign Office in foreign a counterpart application not more than 30 days prior to the filing of this IDS; or b. each item of information contained in the IDS was first cited in any communication from a foreign Office in a counterpart application not more than three months prior to the filing of this IDS; or no item of information contained in the IDS was c. cited in a communication from a foreign Patent Office in a counterpart foreign application, and, the knowledge of the person signing the certification after making reasonable inquiry, no IDS was known to any item of individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS. d. Some of the items of information were cited in a П communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Office Patent counterpart foreign in a application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this

statement.

VII. PAYMENT	OF FI	EES (check	one box)	
	.R.		mount of \$180.00 as required by 37 is enclosed for the above-identified	
amo	Please charge Deposit Account No. 02-2448 in the amount required by 37 C.F.R. § 1.17(p) for the above indicated fee. This paper is submitted in triplicate.			
⊠ No	No fee is required.			
he/she is r determined th the PTO is re	eques at t eques	sted to c his IDS hated to con	any questions concerning this IDS, ontact the undersigned. If it is as been filed under the wrong rule, sider this IDS under the proper rule ee to Deposit Account No. 02-2448.	
this, concurred this credit any or	rent, verpa es r	and futury and to lead to the second and the second	mmissioner is hereby authorized in ure replies, to charge payment or Deposit Account No. 02-2448 for any der 37 C.F.R. § 1.16 or under § 1.17; ime fees.	
			Respectfully submitted,	
			BIRCH, STEWART, KOLASCH & BIRCH, LLP	
			By Mark/J. Nuell, #36,623	
DRN:trb 0020-5314PUS1			P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000	
Attachment(s)	: ⊠	PTO-1449		
	\boxtimes	Documents		
		Foreign Se	earch Report	
		Fee		
		Othor.		